Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
第一作者:
James J,McGough
第一单位:
Semel Institute for Neuroscience and Human Behavior, and David Geffen School of Medicine at UCLA, 300 UCLA Medical Plaza, Los Angeles, CA 90095, USA. jmcgough@mednet.ucla.edu
作者:
医学主题词
青少年(Adolescent);厌食(Anorexia);注意力缺陷障碍伴多动(Attention Deficit Disorder with Hyperactivity);中枢神经系统刺激剂(Central Nervous System Stimulants);用药计划表(Drug Administration Schedule);头痛(Headache);人类(Humans);哌醋甲酯(Methylphenidate);入睡和睡眠障碍(Sleep Initiation and Maintenance Disorders);体重减轻(Weight Loss)
DOI
10.1089/cap.2006.16.351
PMID
16768642
发布时间
2013-11-21
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



